Nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias
Ended Project Grant Awarded Last action
- Award ID
- R44DK115290
- Recipient
-
Crinetics Pharmaceuticals, Inc. UEI MJZFLM2TGRZ8
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,192,916
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $896,817 | |
| Amendment | $998,741 | |
| Amendment | $0 | |
| Original award | $297,358 |
Quick answers
Who received award R44DK115290?
R44DK115290 was awarded to Crinetics Pharmaceuticals, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on August 1, 2017.
How much is award R44DK115290 worth?
$2,192,916 has been obligated on R44DK115290.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award